Enoxaparin Dosing for VTE Prophylaxis in Patients with Severe Renal Impairment

Rationale for Dosing Decision

The American College of Cardiology recommends that for patients with severe renal insufficiency (CrCl <30 mL/min), the enoxaparin dose should be reduced to 30 mg subcutaneously once daily for prophylaxis, regardless of body weight, due to a 44% reduction in enoxaparin clearance and significantly increased bleeding risk 1, 2
The 2014 ACC/AHA guidelines state that for enoxaparin prophylaxis with CrCl <30 mL/min, the dose should be reduced to 1 mg/kg every 24 hours (for therapeutic dosing) or avoided altogether, with similar reductions for prophylactic regimens, based on moderate-quality evidence 2
Multiple guidelines, including the National Comprehensive Cancer Network, consistently recommend 30 mg once daily for prophylactic dosing in severe renal impairment, superseding weight-based adjustments, with a strong recommendation based on high-quality evidence 1, 3

The American College of Cardiology recommends monitoring anti-Xa levels in patients with severe renal impairment and morbid obesity, with a target prophylactic range of 0.2-0.5 IU/mL measured 4-6 hours after dosing, based on moderate-quality evidence 1, 4
The guidelines suggest checking anti-Xa levels after 3-4 doses to ensure adequate anticoagulation without excessive accumulation, with a strong recommendation based on high-quality evidence 1

Unfractionated heparin (UFH) 5000 units subcutaneously every 8-12 hours may be preferable to enoxaparin in patients with severe renal impairment due to hepatic rather than renal elimination, shorter half-life, and reversibility with protamine, based on low-quality evidence 1, 4

The American College of Cardiology recommends against using standard obesity-adjusted doses (40 mg every 12 hours or weight-based 0.5 mg/kg every 12 hours) in patients with severe renal impairment, due to unacceptable bleeding risk, with a strong recommendation based on high-quality evidence 1, 4
If anti-Xa levels on 30 mg daily dosing are subtherapeutic (<0.2 IU/mL), consideration should be given to switching to UFH rather than escalating enoxaparin dose, based on moderate-quality evidence 1